베돌리주맙 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global vedolizumab market size is expected to reach USD 6.03 Billion in 2034 from USD 2.95 Billion in 2025, growing at a CAGR of 8.27 during 2026-2034.This market has demonstrated significant growth owing to increasing prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Vedolizumab has emerged as an important biologic therapy due to its targeted mechanism of action and effectiveness in managing chronic gastrointestinal inflammation. Growing awareness regarding advanced treatment options and improving diagnosis rates have contributed to higher adoption levels. Expanding healthcare access and increased investment in biologic therapies have further supported market development.

Key growth drivers include rising incidences of autoimmune disorders, growing demand for targeted biologic treatments, and advancements in gastrointestinal disease management. Healthcare providers are increasingly adopting therapies that offer improved efficacy and safety profiles for long-term disease control. Favorable clinical outcomes and expanding treatment guidelines have strengthened market demand. Additionally, increasing healthcare expenditures and ongoing research initiatives are supporting broader utilization of advanced biologic medications.

Future prospects remain promising as research efforts continue to enhance treatment strategies for inflammatory bowel diseases. Expanding access to specialty healthcare services and growing patient awareness are expected to support market growth. The development of new formulations and improved delivery methods may further enhance treatment convenience and adherence. As healthcare systems increasingly prioritize personalized medicine and advanced biologic therapies, demand for vedolizumab is likely to remain strong.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Route of Administration

• Subcutaneous Injection
• Intravenous Infusion

By Treatment Line

• First-Line Therapy
• Second-Line Therapy

By Indication

• Ulcerative Colitis (UC)
• Crohn's Disease (CD)

By End Use

• Hospitals
• Clinics
• Ambulatory Care
• Home Care

COMPANIES PROFILED

• AbbVie Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Eli Lilly and Company, Bristol Myers Squibb, UCB Pharma, Amgen Inc., Roche Holding AG, Polpharma Biologics, Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VEDOLIZUMAB MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Route Of Administration
• 4.2. Subcutaneous Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Intravenous Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VEDOLIZUMAB MARKET: BY TREATMENT LINE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Line
• 5.2. First-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Second-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VEDOLIZUMAB MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Ulcerative Colitis (UC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Crohn's Disease (CD) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VEDOLIZUMAB MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ambulatory Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VEDOLIZUMAB MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Route Of Administration
  • 8.2.2 By Treatment Line
  • 8.2.3 By Indication
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Route Of Administration
  • 8.3.2 By Treatment Line
  • 8.3.3 By Indication
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Route Of Administration
  • 8.4.2 By Treatment Line
  • 8.4.3 By Indication
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Route Of Administration
  • 8.5.2 By Treatment Line
  • 8.5.3 By Indication
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Route Of Administration
  • 8.6.2 By Treatment Line
  • 8.6.3 By Indication
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL VEDOLIZUMAB INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.3 Pfizer Inc
  • 10.2.4 Eli Lilly And Company
  • 10.2.5 Bristol Myers Squibb
  • 10.2.6 UCB Pharma
  • 10.2.7 Amgen Inc
  • 10.2.8 Roche Holding AG
  • 10.2.9 Polpharma Biologics
  • 10.2.10 Takeda Pharmaceutical Company Limited